

CORRECTION

Open Access



Correction: Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis

Kevin Y. Xu^{1*†}, Jennifer K. Bello^{2†}, Joanna Buss³, Hendrée E. Jones⁴, Laura J. Bierut¹, Dustin Stwalley³, Hannah S. Szlyk¹, Caitlin E. Martin⁵, Jeannie C. Kelly⁶, Ebony B. Carter⁴, Elizabeth E. Krans^{7†} and Richard A. Grucza^{2†}

Correction: *Addict Sci Clin Pract* 20, 1 (2025)
<https://doi.org/10.1186/s13722-024-00530-1>

Following publication of the original article [1], the authors noticed an error in the language used to describe the cohort development protocol, as well as the associated Fig. 1.

In the **Data sources and cohort development** section, one sentence is changed from:

“People who initiated BUP or PSY before pregnancy ($n=4,396$) were excluded, thus limiting our sample of participants to those who newly initiated BUP or PSY during pregnancy.”

To:

People who initiated BUP or PSY after delivery ($n=4,396$) were excluded, thus limiting our sample of participants to those who newly initiated BUP or PSY during pregnancy.

[†]Kevin Y. Xu, Jennifer K. Bello, Elizabeth E. Krans and Richard A. Grucza contributed equally to this work.

The online version of the original article can be found at <https://doi.org/10.1186/s13722-024-00530-1>.

*Correspondence:

Kevin Y. Xu
xukeviny@wustl.edu

¹Health and Behavior Research Center, Division of Addiction Science, Prevention and Treatment, Department of Psychiatry, Renard Hospital 3007A, Washington University School of Medicine, 4940 Children's Place, Saint Louis, MO 63110, USA

²Departments of Family and Community Medicine and Health and Clinical Outcomes Research, Saint Louis University School of Medicine, Saint Louis, MO, USA

³Institute for Informatics, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA

⁴Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

⁵Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA

⁶Division of Maternal-Fetal Medicine & Ultrasound, Department of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, MO, USA

⁷Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Fig. 1 is changed from:

70,993 Medicaid-enrolled women with OUD initiating either buprenorphine (BUP) or psychosocial services (PSY) without medication

- ➔ Excluded 55,479 because no date of conception (estimated from date of delivery per Sentinel algorithm) in the 210 days before treatment initiation

15,514 pregnant persons with OUD who received either BUP or PSY

- ➔ Excluded 4,396 people initiating treatment after delivery

11,118 pregnant persons with OUD who initiated either BUP or PSY during pregnancy

- 7,675 initiating psychosocial services without medication (PSY)
- 3,443 initiating buprenorphine (BUP)

Fig. 1 Derivation of the analytic sample

To:

70,993 Medicaid-enrolled women with OUD initiating either buprenorphine (BUP) or psychosocial services (PSY) without medication

- ➔ Excluded 55,479 because no date of conception (estimated from date of delivery per Sentinel algorithm) in the 210 days before treatment initiation

15,514 pregnant persons with OUD who received either BUP or PSY during pregnancy (date of conception in the 210 days before treatment initiation)

- ➔ Excluded 4,396 people initiating treatment after delivery

11,118 pregnant persons with OUD who initiated either BUP or PSY during pregnancy

- 7,675 initiating psychosocial services without medication (PSY)
- 3,443 initiating buprenorphine (BUP)

Fig. 1 Derivation of the analytic sample

The authors apologise for this error and regret any inconvenience caused.

The original article [1] has been updated.

Published online: 11 March 2025

Reference

1. Xu KY, Bello JK, Buss J, et al. Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis. *Addict Sci Clin Pract.* 2025;20:1. <https://doi.org/10.1186/s13722-024-00530-1>.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.